Home > Business Cases > Relating mechanism of action and drug efficacy of HDAC inhibitors
Relating mechanism of action and drug efficacy of HDAC inhibitors
Situation
Same previous company with HDAC inhibitors wanted to explore the use of the selected compound in certain cancer type, in combination with a standard of care in this indication
Anaxomics Strategy
Again, Anaxomics created the biological map and the model around drug targets and mechanisms and pathways related in targeted cancer type, and developed the model that explained known data about efficacy of drugs whose targets were contained in the map and the model.
Specifically, Anaxomics explored the potential mechanistically synergistic effect of the client's compound and the standard of care drug.
Solution and Practical Use
Currently, this analysis plus other preclinical data are being used by the Client to defend in front of regulatory agencies the use of the combination in Phase II trial.
Please, contact us here to request more information.
